Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751619 | 1.00 | MAPT (0.47) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751741 | 0.99 | MAPT (0.48) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751488 | 0.89 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751571 | 0.89 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751504 | 0.89 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751709 | 0.88 | MAPT (0.49) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751513 | 0.88 | MAPT (0.49) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751484 | 0.87 | MAPT (0.50) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751622 | 0.84 | BCL2 (0.52) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL23165503 | 0.81 | MAPT (0.55) | MAPTPKMPOLBSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | MAPT 4392/4885PKM 2525/4885POLB 1338/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | MAPT 4392/4885PKM 2525/4885POLB 1338/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | MAPT 4406/4885PKM 2342/4885POLB 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.